Flagellate Hyperpigmentation Following Treatment with Low-Dose Bleomycine: Report of two cases
PDF
Cite
Share
Request
Case report
P: 134-138
2015

Flagellate Hyperpigmentation Following Treatment with Low-Dose Bleomycine: Report of two cases

Acta Haematol Oncol Turc 2015;48(3):134-138
1. Department Of Medical Oncology, Kent Hospital, Izmir, Turkey
2. Department Of Medical Oncology, Aydin State Hospital, Aydin, Turkey
3. Department Of Medical Oncology, Ataturk Research And Training Hospital, Katip Celebi University, Izmir, Turkey
4.
No information available.
No information available
Received Date: 2015-01-20T20:38:02
Accepted Date: 2015-12-10T14:19:20
PDF
Cite
Share
Request

Abstract

Mucocutaneus side effects of bleomycin therapy are common in patients receiving cumulative doses greater than 100 U (100 mg). Flagellate hyperpigmentation is an interesting cutaneus reaction caused by bleomycin use, and is seen in about 8-20% of cases. The mechanism is unknown. Diagnosis is based on its characteristic clinical appearance. Histological examination of hyperpigmented skin lesions has demonstrated increased melanin content in basal keratinocytes. It has been suggested that mild cases may respond to antihistamines and ⁄ or systemic steroids, but in many cases discontinuation of the drug may be necessary. We present two patients (cumulative doses of 30 and 38 U) that developed bleomycin-induced flagellate hyperpigmentation with relatively low doses. Because the condition is not uncommon in patients who are using this drug, the clinician should be mindful of this complication.